NO20073732L - Arylpiperazinderivater og anvendelse derav som 5-HT1A-receptorligander - Google Patents

Arylpiperazinderivater og anvendelse derav som 5-HT1A-receptorligander

Info

Publication number
NO20073732L
NO20073732L NO20073732A NO20073732A NO20073732L NO 20073732 L NO20073732 L NO 20073732L NO 20073732 A NO20073732 A NO 20073732A NO 20073732 A NO20073732 A NO 20073732A NO 20073732 L NO20073732 L NO 20073732L
Authority
NO
Norway
Prior art keywords
receptor ligands
arylpiperazine derivatives
ht1a receptor
ht1a
derivatives
Prior art date
Application number
NO20073732A
Other languages
English (en)
Inventor
Bellinda Benhamu Salama
Maria Luz Lopez Rodriguez
Margarita Valhondo Falcon
Original Assignee
Schwarz Pharma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schwarz Pharma Sl filed Critical Schwarz Pharma Sl
Publication of NO20073732L publication Critical patent/NO20073732L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Nye substituerte arylpiperazinderivater med aktivitet som 5-hydroksytryptamin 1A (5-HT1A) reseptorundertypeligander, deres stereokjemiske isomerer, fremgangsmåter for deres fremstilling og deres anvendelse og farmasøytiske preparater som inneholder dem for behandling av Parkinsons sykdom, cerebral skade ved tromboembolisk ictus, craneoencefaliske traumer, depresjon, migrene, smerte, psykose, angstforstyrrelser, aggressive forstyrrelser eller urinveiforstyrrelser.
NO20073732A 2004-12-27 2007-07-18 Arylpiperazinderivater og anvendelse derav som 5-HT1A-receptorligander NO20073732L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04106998A EP1674103A1 (en) 2004-12-27 2004-12-27 Arylpiperazine derivatives and use thereof as 5-HT1A receptor ligands
PCT/EP2005/057175 WO2006069993A1 (en) 2004-12-27 2005-12-27 Arylpiperazine derivatives and use thereof as 5-ht1a receptor ligands

Publications (1)

Publication Number Publication Date
NO20073732L true NO20073732L (no) 2007-09-18

Family

ID=34930175

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073732A NO20073732L (no) 2004-12-27 2007-07-18 Arylpiperazinderivater og anvendelse derav som 5-HT1A-receptorligander

Country Status (14)

Country Link
US (1) US20090036455A1 (no)
EP (2) EP1674103A1 (no)
JP (1) JP2008525384A (no)
KR (1) KR20070097419A (no)
CN (1) CN101087610A (no)
AU (1) AU2005321228A1 (no)
BR (1) BRPI0519269A2 (no)
CA (1) CA2582663A1 (no)
EA (1) EA200701052A1 (no)
IL (1) IL181955A0 (no)
MX (1) MX2007006842A (no)
NO (1) NO20073732L (no)
WO (1) WO2006069993A1 (no)
ZA (1) ZA200702457B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2199086B1 (es) 2002-07-31 2005-06-01 Cepa Schwarz Pharma Sl Nuevos derivados de cicloalcanodionas, procedimiento para su preparacion y sus aplicaciones farmacologicas.
WO2023135528A1 (en) 2022-01-11 2023-07-20 Suven Life Sciences Limited Heteroalicyclic derivatives and their use in the treatment of cns disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3079295A (en) * 1994-09-01 1996-03-22 Universidad Complutense De Madrid New arylpiperazine derivatives

Also Published As

Publication number Publication date
KR20070097419A (ko) 2007-10-04
EP1830854A1 (en) 2007-09-12
MX2007006842A (es) 2007-08-08
WO2006069993A1 (en) 2006-07-06
US20090036455A1 (en) 2009-02-05
EP1674103A1 (en) 2006-06-28
ZA200702457B (en) 2008-04-30
CN101087610A (zh) 2007-12-12
JP2008525384A (ja) 2008-07-17
IL181955A0 (en) 2007-07-04
AU2005321228A1 (en) 2006-07-06
CA2582663A1 (en) 2006-07-06
EA200701052A1 (ru) 2008-02-28
BRPI0519269A2 (pt) 2009-01-06

Similar Documents

Publication Publication Date Title
NO20076638L (no) Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
NO20083197L (no) Substituert cinnolin-derivater som GABAA-reseptor modulatorer og metode for deres syntese
Jin et al. Computational fragment-based design facilitates discovery of potent and selective monoamine oxidase-B (MAO-B) inhibitor
NO20064151L (no) Nye forbindelser
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20055219L (no) Nye forbindelser
NO20071660L (no) Nye pyridinonderivater og deres anvendelse som positive allosteriske modulatorer av MGLUR2-reseptorer
ATE423769T1 (de) Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
ES2282685T3 (es) Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer.
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
DK1716152T3 (da) Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
NO20090266L (no) Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer
CN104059013B8 (zh) 1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途
NO20064156L (no) Indazolkarboksamidforbindelser som 5-HT4 receptoragonister
NO20082679L (no) Sammensetning og fremgangsmate for a behandle CNS lidelser
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
NO20084567L (no) Polymorfe former av (2S) - (4E) -N-metyl-5-(3-isopropoksypyridin)yl]-4-penten-2-amin for behandling av sykdommer i sentralnervesystemet
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
BRPI0508724A (pt) derivados do fenilaminoetanol como agonistas do receptor beta2
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application